Richard A. Heyman, Director at Enliven Therapeutics, Inc. (ELVN), sold 26,220 shares at $25.00 ($656K) on 2026-01-08, disclosed to the SEC on 2026-01-12.
Open-market sale of $656k ELVN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.00 | 1,620 | $41K | 6.2% |
| 2 | $25.04 | 8,015 | $201K | 30.6% |
| 3 | $25.04 | 8,015 | $201K | 30.6% |
| 4 | $25.00 | 4,285 | $107K | 16.3% |
| 5 | $25.00 | 4,285 | $107K | 16.3% |
| Total | $25.02 avg | 26,220 |
| $656K |
| 100% |
| Filing → |
| ELVN | SELL | 2026-02-19 | $32K | — | Filing → |
| ELVN | SELL | 2026-01-22 | $33K | — | Filing → |
| ORIC | SELL | 2026-01-20 | $80K | — | Filing → |